Skip to main content
SpringerLink
Log in

Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial

  • Infertility: Short Communication
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Polycystic ovary syndrome (PCOS) is a common cause of female infertility, affecting 5–10% of women of reproductive age. Many studies have reported improvement in insulin resistance and thereby intracellular glucose uptake after myo-inositol treatment in PCOS patients, but these studies have a small sample size, varying methodology, and outcome analysis. Therefore, we designed a present meta-analysis of randomized controlled trials to explore the effect of myo-inositol supplementation on anthropometric, metabolic, and endocrine outcomes in PCOS patients. Randomized controlled trials assessing the effectiveness of myo-inositol were identified in electronic databases like PubMed, Cochrane, Embase, MEDLINE, CINAHL, and AMED. Listed references and citations of related articles were also screened manually to identify additional studies. Research papers for which full-text copies were not available on scientific databases were procured from respective authors. Thereafter, data were extracted from included studies and analyzed using RevMan 5.3 of the Cochrane Collaboration. A total of 17 randomized controlled trials with 1083 PCOS patients were included in this meta-analysis. Among the 17 trials, 7 trials compared myo-inositol with folic acid, 8 trials compared myo-inositol with metformin, and 2 trials compared myo-inositol with oral contraceptives. No significant improvement in body mass index, waist-to-hip ratio, fasting insulin, fasting glucose, HOMA, LH, FSH, estradiol, sex hormone-binding globulin, dehydroepiandrosterone, and total testosterone levels were observed after myo-inositol treatment in PCOS patients except androstenedione and prolactin levels. Clinically significant improvement was not observed in anthropometric, metabolic, and endocrine outcomes after myo-inositol treatment in PCOS patients. However, heterogeneity between studies was high.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Data Availability

Data used during the study appear in the submitted article.

Code Availability

RevMan 5.3 from Cochrane Collaboration.

Abbreviations

A:

Androstenedione

BMI:

Body mass index

DCI:

D-Chiro-inositol

DHEAS:

Dehydroepiandrosterone sulfate

FG:

Fasting glucose

FI:

Fasting insulin

FSH:

Follicle-stimulating hormone

HOMA:

Homeostatic model assessment

IR:

Insulin resistance

LH:

Luteinizing hormone

MI:

Myo-inositol

P:

Prolactin

PCOS:

Polycystic ovary syndrome

SHBG:

Sex hormone-binding globulin

T:

Total testosterone

WHR:

Waist-to-hip ratio

References

  1. Robert J, Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;9588:685–97.

    Google Scholar 

  2. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–9. https://doi.org/10.1210/jcem.84.1.5393.

    Article  CAS  PubMed  Google Scholar 

  3. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–6. https://doi.org/10.2337/diacare.22.1.141.

    Article  CAS  PubMed  Google Scholar 

  4. Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013;56:137. https://doi.org/10.5468/ogs.2013.56.3.137.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86:2453–5. https://doi.org/10.1210/jcem.86.6.7580.

    Article  CAS  PubMed  Google Scholar 

  6. Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004;89:5592–6. https://doi.org/10.1210/jc.2004-0751.

    Article  CAS  PubMed  Google Scholar 

  7. Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2011;26:2442–51. https://doi.org/10.1093/humrep/der197.

    Article  CAS  PubMed  Google Scholar 

  8. Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2012;97:225–30. https://doi.org/10.1016/j.fertnstert.2011.10.022.

    Article  PubMed  Google Scholar 

  9. Kabel AM. Journal of pharmacological reports polycystic ovarian syndrome : insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment. J Pharmacol Rep. 2016;1:1–5.

    Google Scholar 

  10. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81:114–9. https://doi.org/10.1016/j.fertnstert.2003.05.020.

    Article  CAS  PubMed  Google Scholar 

  11. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999;48:167–72. https://doi.org/10.1016/s0026-0495(99)90028-8.

    Article  CAS  PubMed  Google Scholar 

  12. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96:801–10. https://doi.org/10.1172/JCI118126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B, et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. 2008;23:153–9. https://doi.org/10.1093/humrep/dem356.

    Article  CAS  PubMed  Google Scholar 

  14. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72:83–9. https://doi.org/10.1210/jcem-72-1-83.

    Article  CAS  PubMed  Google Scholar 

  15. Pugeat M, Crave JC, Elmidani M, Nicolas MH, Garoscio-Cholet M, Lejeune H, et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol. 1991;40:841–9. https://doi.org/10.1016/0960-0760(91)90310-2.

    Article  CAS  PubMed  Google Scholar 

  16. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O’Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003;79:932–7. https://doi.org/10.1016/s0015-0282(02)04914-2.

    Article  PubMed  Google Scholar 

  17. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab. 1996;81:302–9. https://doi.org/10.1210/jcem.81.1.8550768.

    Article  CAS  PubMed  Google Scholar 

  18. The Practice Committee of the American Society for Reproductive Medicine. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Fertil Steril. 2004;82:181–3. https://doi.org/10.1016/j.fertnstert.2004.05.041.

    Article  Google Scholar 

  19. Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016;12:1181–96. https://doi.org/10.1080/17425255.2016.1206887.

    Article  CAS  PubMed  Google Scholar 

  20. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443:651–7. https://doi.org/10.1038/nature05185.

    Article  CAS  PubMed  Google Scholar 

  21. Unfer V, Dinicola S, Lagana AS, Bizzarri M. Altered ovarian inositol ratios may account for pathological steroidogenesis in PCOS. Int J Mol Sci. 2020;21:7157. https://doi.org/10.3390/ijms21197157.

    Article  CAS  PubMed Central  Google Scholar 

  22. Regidor PA, Schindler AE, Lesoine B, Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm Mol Biol Clin Investig. 2018. https://doi.org/10.1515/hmbci-2017-0067.

  23. Kamenov Z, Gateva A. Inositols in pcos. Molecules. 2020;25:1–21. https://doi.org/10.3390/molecules25235566.

    Article  CAS  Google Scholar 

  24. Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2017;96:1–8. https://doi.org/10.1097/MD.0000000000008842.

    Article  CAS  Google Scholar 

  25. Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol. 2016;2016:1–12. https://doi.org/10.1155/2016/1849162.

    Article  CAS  Google Scholar 

  26. Facchinetti F, Orru B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35:198–206. https://doi.org/10.1080/09513590.2018.1540578.

    Article  CAS  PubMed  Google Scholar 

  27. Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS : a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6:647–58. https://doi.org/10.1530/EC-17-0243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zeng L. Effectiveness of myoinositol for polycystic ovary syndrome : a systematic review and meta-analysis. Endocrine. 2018;59:30–8. https://doi.org/10.1007/s12020-017-1442-y.

    Article  CAS  PubMed  Google Scholar 

  29. Pundir J, Psaroudakis D, Savnur P, Bhide P, Sabatini L, Teede H, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome : a meta-analysis of randomised trials. An Int J Obstet Gynaecol. 2017;125:299–308. https://doi.org/10.1111/1471-0528.14754.

    Article  CAS  Google Scholar 

  30. Arentz S, Smith CA, Abbott J, Bensoussan A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome : a systematic review and meta-analysis. BMC Complement Altern Med. 2017;17:500–14. https://doi.org/10.1186/s12906-017-2011-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-34. https://doi.org/10.1016/j.jclinepi.2009.06.006.

    Article  PubMed  Google Scholar 

  32. RevMan Web 2020. The Cochrane Collaberation 2020.

  33. Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29:375–9. https://doi.org/10.3109/09513590.2012.743020.

    Article  CAS  PubMed  Google Scholar 

  34. Costantino D, Ostantino G, Minozzi G, Minozzi F, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13:105–10.

    CAS  PubMed  Google Scholar 

  35. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:139–44. https://doi.org/10.1080/09513590801893232.

    Article  CAS  PubMed  Google Scholar 

  36. Donà G, Sabbadin C, Fiore C, Bragadin M, Giorgino FL, Ragazzi E, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012;166:703–10. https://doi.org/10.1530/EJE-11-0840.

    Article  CAS  PubMed  Google Scholar 

  37. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009;91:1750–4. https://doi.org/10.1016/j.fertnstert.2008.01.088.

    Article  CAS  PubMed  Google Scholar 

  38. Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017;33:39–42. https://doi.org/10.1080/09513590.2016.1236078.

    Article  CAS  PubMed  Google Scholar 

  39. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010;26:275–80. https://doi.org/10.3109/09513590903366996.

    Article  CAS  PubMed  Google Scholar 

  40. Tagliaferri V, Romualdi D, Immediata V, De Cicco S, Di Florio C, Lanzone A, et al. Metformin versus myoinositol: which is better in obese PCOS patients? A randomized controlled crossover study. Clin Endocrinol (Oxf). 2017;86:725–30. https://doi.org/10.1111/ijlh.12426.

    Article  CAS  Google Scholar 

  41. De Leo V, Musacchio M, Cappelli V, Sabatino A, Tosti C, Piomboni P. A Combined treatment with myo-inositol and monacolin K improve the androgen and lipid profiles of insulin-resistant PCOS patients. J Metab Syndr. 2013;2:1–5. https://doi.org/10.4172/2167-0943.1000127.

    Article  Google Scholar 

  42. Pourghasem S, Bazarganipour F, Taghavi SA, Kutenaee MA. The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. Arch Gynecol Obstet. 2019;299:1193–9. https://doi.org/10.1007/s00404-019-05064-5.

    Article  CAS  PubMed  Google Scholar 

  43. Jamilian H, Jamilian M, Foroozanfard F, Afshar Ebrahimi F, Bahmani F, Asemi Z. Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. J Psychosom Obstet Gynecol. 2018;39:307–14. https://doi.org/10.1080/0167482X.2017.1383381.

    Article  Google Scholar 

  44. Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, Vahedpoor Z, Aghadavod E, Ghaderi A, et al. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecol Endocrinol. 2019;35:406–11. https://doi.org/10.1080/09513590.2018.1540570.

    Article  CAS  PubMed  Google Scholar 

  45. Angik R. a Comparative study of metabolic and hormonal effects of myoinositol Vs metformin in women with polycystic ovary syndrome: a randomised controlled trial. Int J Reprod Contraception, Obstet Gynecol. 2015;4. https://doi.org/10.5455/2320-1770.ijrcog20150234.

  46. Nehra J, Kaushal J, Singhal SR, Ghalaut VS. Comparision of myo-inositol versus metformin on anthropometric parameters in polycystic ovarian syndrome in women. Int J Pharm Pharm Sci. 2017;9:144–8. https://doi.org/10.22159/ijpps.2017v9i4.16359.

    Article  CAS  Google Scholar 

  47. Ozay AC, Emekci Ozay O, Okyay RE, Cagliyan E, Kume T, Gulekli B. Different effects of myoinositol plus folic acid versus combined oral treatment on androgen levels in PCOS women. Int J Endocrinol. 2016;2016:1–8. https://doi.org/10.1155/2016/3206872.

    Article  CAS  Google Scholar 

  48. Pkhaladze L, Barbakadze L, Kvashilava N. Myo-inositol in the treatment of teenagers affected by PCOS. Int J Endocrinol. 2016;2016. https://doi.org/10.1155/2016/1473612.

  49. Pasquali R, Stener-Victorin E, Yildiz BO, Duleba AJ, Hoeger K, Mason H, et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol (Oxf). 2011;74:424–33.

    Article  Google Scholar 

  50. Pauli JM, Raja-Khan N, Wu X, Legro RS. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med. 2011;28:1445–54. https://doi.org/10.1111/J.1464-5491.2011.03460.X.

    Article  CAS  PubMed  Google Scholar 

  51. Hruby A, Hu FB. The epidemiology of obesity: A big picture. Pharmacoeconomics. 2015;33:673–89. https://doi.org/10.1007/s40273-014-0243-x.The.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31:2841–55. https://doi.org/10.1093/HUMREP/DEW218.

    Article  PubMed  Google Scholar 

  53. Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35:198–206. https://doi.org/10.1080/09513590.2018.1540578.

    Article  CAS  PubMed  Google Scholar 

  54. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28:509–15. https://doi.org/10.3109/09513590.2011.650660.

    Article  CAS  PubMed  Google Scholar 

  55. Barber TM, Dimitriadis GK, Andreou A, Franks S. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. Clin Med (Northfield Il). 2016;16:262–6. https://doi.org/10.7861/clinmedicine.16-3-262.

    Article  Google Scholar 

  56. Dona G, Sabbadin C, Fiore C, Bragadin M, Giorgino FL, Ragazzi E, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012;166:703–10. https://doi.org/10.1530/EJE-11-0840.

    Article  CAS  PubMed  Google Scholar 

  57. Bhide P, Pundir J, Gudi A, Shah A, Homburg R, Acharya G. The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI : a systematic review and meta - analysis. Acta Obstet Gynecol Scand. 2019;98:1235–44. https://doi.org/10.1111/aogs.13625.

    Article  CAS  PubMed  Google Scholar 

  58. Ibanez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017;88:371–95. https://doi.org/10.1159/000479371.

    Article  CAS  PubMed  Google Scholar 

  59. Haring R, Friedrich N, Völzke H, Vasan RS, Felix SB, Dörr M, et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J. 2014;35:1215–21. https://doi.org/10.1093/EURHEARTJ/EHS233.

    Article  CAS  PubMed  Google Scholar 

  60. Yang H, Di J, Pan J, Yu R, Teng Y, Cai Z, et al. The association between prolactin and metabolic parameters in PCOS women: a retrospective analysis. Front Endocrinol (Lausanne). 2020;11:1–9. https://doi.org/10.3389/fendo.2020.00263.

    Article  CAS  Google Scholar 

  61. Georgopoulos NA, Papadakis E, Armeni AK, Katsikis I, Roupas ND, Panidis D. Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones. 2014;13:213–21. https://doi.org/10.1007/BF03401335.

    Article  PubMed  Google Scholar 

  62. O’Reilly MW, Taylor AE, Crabtree NJ, Hughes BA, Capper F, Crowley RK, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab. 2014;99:1027. https://doi.org/10.1210/JC.2013-3399.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Gerli S, Papaleo E, Ferrari A, di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347–54.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dr. Niranjan Kanaki who critically reviewed the English language of the manuscript.

Funding

The present meta-analysis is not funded by a specific project grant.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Pharmacy Practice, K. B. Institute of Pharmaceutical Education and Research, Near Gh-6 circle, Sector-23, Gandhinagar, 382023, Gujarat, India

    Hardik Jethaliya, Nirva Gajjar, Vrushank Patel, Shrikalp Deshpande & Roshni Patel

Authors
  1. Hardik Jethaliya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nirva Gajjar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vrushank Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shrikalp Deshpande
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roshni Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H. J.: analysis and interpretation of data, acquisition of data, drafting the manuscript; N. G.: analysis and interpretation of data, acquisition of data, drafting the manuscript; V. P.: analysis and interpretation of data, acquisition of data, drafting the manuscript; S. D.: critical revision of the manuscript; R. P.: conception and design, interpretation of data, critical revision of the manuscript.

Corresponding author

Correspondence to Roshni Patel.

Ethics declarations

Ethical Approval

No ethics committee approval was required because the study analyzed only published data.

Consent to Participate

Not applicable.

Consent for Publication

All authors have read and agreed to the published version of the manuscript.

Conflict of Interest

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jethaliya, H., Gajjar, N., Patel, V. et al. Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. Reprod. Sci. 29, 2282–2298 (2022). https://doi.org/10.1007/s43032-022-00933-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43032-022-00933-y

Keywords

Search

Navigation